Loading
Life sciences · Journal article
Biomacromolecules · September 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Inspired by the DNA-cleaving potency of natural enediynes such as calicheamicin, we report the design and synthesis of maleimide−enediyne conjugates integrated into poly(ε-caprolactone) (PCL) as a next-generation platform for anticancer drug delivery. Maleimide-based enediynes typically suffer from poor aqueous solubility and nonspecific toxicity, addressed here by covalently incorporating enediyne groups into amphiphilic PCL block copolymers via post-polymerization functionalization. The resulting polymers form ∼120 nm spherical micelles with a critical micelle concentration of 9.1 × 10−4 mg mL−1, enhancing enediyne solubility, promoting tumor accumulation through the EPR effect, and enabling encapsulation of hydrophobic drugs such as doxorubicin. Electron paramagnetic resonance confirmed radical formation and Bergman cyclization under physiological conditions. Cell viability assays showed enediyne-induced death in MDA-MB-231 breast cancer cells, and the functionalized PCL exhibited in vitro DNA cleaving activity, demonstrating that maleimide−enediyne-functionalized PCL micelles are promising platforms for cancer chemotherapy.